To build the modern drug-discovery engine: the disciplines, the data and the drug hunters tuned to one target that accelerates development, lowers cost, and de-risks the regulatory path.
Architect and run a discovery engine around each partner’s problem- the right experiments in the right order, each result feeding the next decision, one team accountable end to end.
one team, not a chain of vendors.
people who ran these disciplines in industry.
the right tool for each decision, including NAMs, chosen on the merits.
a full bench with no fixed overhead.
Despite countless therapies, 90% of drugs fail in clinical trials due to non-predictive preclinical models. SPECCRO is changing that.
Each failed candidate costs $2.0- $2.5 Billion.
Backed by scientific advances and recent FDA and EMA reforms, NAMs now have clear regulatory momentum as credible alternatives to animal testing.